Multimedia Library

2023 Preview

Biotech and pharma: from bad to worse, or better in 2023? Amy Brown and Edwin Elmhirst from Evaluate Vantage, discuss what the coming year is likely to bring.

Biopharma 2022: What's Next?

After getting off to a pretty dismal start, what does the rest of the year hold for the biopharma market?